Michael Cherny
Stock Analyst at Leerink Partners
(4.38)
# 307
Out of 5,161 analysts
119
Total ratings
60.23%
Success rate
14.75%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: Market Perform | $8.5 → $5.5 | $5.36 | +2.61% | 2 | Feb 26, 2026 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $20 → $18 | $23.84 | -26.59% | 11 | Feb 24, 2026 | |
| HSIC Henry Schein | Maintains: Market Perform | $75 → $87 | $74.97 | +16.05% | 3 | Feb 24, 2026 | |
| ACH Accendra Health | Maintains: Market Perform | $3 → $2.75 | $2.36 | +16.53% | 1 | Feb 20, 2026 | |
| XRAY DENTSPLY SIRONA | Upgrades: Buy | $13 → $17 | $11.80 | +44.07% | 9 | Feb 19, 2026 | |
| MEDP Medpace Holdings | Maintains: Market Perform | $575 → $485 | $443.85 | +9.27% | 2 | Feb 11, 2026 | |
| CVS CVS Health | Maintains: Buy | $100 → $95 | $76.07 | +24.88% | 12 | Jan 27, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $41.07 | +16.87% | 1 | Jan 12, 2026 | |
| CERT Certara | Upgrades: Outperform | $13 | $6.56 | +98.17% | 2 | Jan 6, 2026 | |
| DGX Quest Diagnostics | Maintains: Outperform | $203 → $210 | $200.88 | +4.54% | 3 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $785 → $850 | $944.36 | -9.99% | 15 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $188 → $186 | $219.09 | -15.10% | 13 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $28 | $17.50 | +60.00% | 11 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $3 | $1.13 | +165.49% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $23 | $25.44 | -9.59% | 11 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $60 → $90 | $24.28 | +270.68% | 2 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $235 → $280 | $166.92 | +67.75% | 3 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $162.93 | +52.21% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $97.45 | +161.67% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $352.65 | -22.02% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $262.91 | -1.11% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $2.21 | +261.99% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $1.66 | +3,062.65% | 2 | Jan 5, 2022 |
Teladoc Health
Feb 26, 2026
Maintains: Market Perform
Price Target: $8.5 → $5.5
Current: $5.36
Upside: +2.61%
Hims & Hers Health
Feb 24, 2026
Maintains: Market Perform
Price Target: $20 → $18
Current: $23.84
Upside: -26.59%
Henry Schein
Feb 24, 2026
Maintains: Market Perform
Price Target: $75 → $87
Current: $74.97
Upside: +16.05%
Accendra Health
Feb 20, 2026
Maintains: Market Perform
Price Target: $3 → $2.75
Current: $2.36
Upside: +16.53%
DENTSPLY SIRONA
Feb 19, 2026
Upgrades: Buy
Price Target: $13 → $17
Current: $11.80
Upside: +44.07%
Medpace Holdings
Feb 11, 2026
Maintains: Market Perform
Price Target: $575 → $485
Current: $443.85
Upside: +9.27%
CVS Health
Jan 27, 2026
Maintains: Buy
Price Target: $100 → $95
Current: $76.07
Upside: +24.88%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $41.07
Upside: +16.87%
Certara
Jan 6, 2026
Upgrades: Outperform
Price Target: $13
Current: $6.56
Upside: +98.17%
Quest Diagnostics
Oct 21, 2025
Maintains: Outperform
Price Target: $203 → $210
Current: $200.88
Upside: +4.54%
Sep 24, 2025
Maintains: Outperform
Price Target: $785 → $850
Current: $944.36
Upside: -9.99%
Aug 12, 2025
Maintains: Outperform
Price Target: $188 → $186
Current: $219.09
Upside: -15.10%
Jul 8, 2025
Upgrades: Outperform
Price Target: $28
Current: $17.50
Upside: +60.00%
May 28, 2025
Downgrades: Market Perform
Price Target: $15 → $3
Current: $1.13
Upside: +165.49%
Apr 29, 2025
Maintains: Buy
Price Target: $26 → $23
Current: $25.44
Upside: -9.59%
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $24.28
Upside: +270.68%
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $166.92
Upside: +67.75%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $162.93
Upside: +52.21%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $97.45
Upside: +161.67%
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $352.65
Upside: -22.02%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $262.91
Upside: -1.11%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $2.21
Upside: +261.99%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $1.66
Upside: +3,062.65%